KEYNOTE-C93/GOG-3064/ENGOT-en15: A phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Brian M. Slomovitz, David Cibula, Tayup Simsek, Mansoor Raza Mirza, Beata Maćkowiak-Matejczk, Emma Hudson, Ignacio Romero, Nicoletta Colombo, Jacob Korach, Rutie Yin, Lucy Gilbert, Kosei Hasegawa, Alexandra Tyulyandina, Sally E. Baron-Hay, Lyndsay Willmott, Floor Jenniskens Backes, Robert J. Orlowski, Xuan Zhou, Vivek Khemka, Sandro Pignata
Institutions: Mount Sinai Medical Center, Charles University, Akdeniz University, Copenhagen University Hospital, Rigshospitalet, Nordic Society of Gynecologic Oncology, Velindre Cancer Centre, Fundación Instituto Valenciano de Oncología, European Institute of Oncology, Tel Aviv University, Sheba Medical Center, Sichuan University, West China Second University Hospital of Sichuan University, McGill University Health Centre, Saitama International Medical Center, Saitama Medical University, Sechenov University, Russian Cancer Research Center NN Blokhin, Royal North Shore Hospital, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Merck & Co., Inc., Rahway, NJ, USA (United States), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Language: English
Subfield: Obstetrics and Gynecology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281666844